Showing 65 news articles about Injectable & long-acting PrEP
Content type: Editors' picks
Topic: Injectable & long-acting PrEP
The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.